There have been no clinically applicable changes as compared to 2011 aside from new details and new tips with regard to the treatment with bisphosphonates and denosumab (see section ‘Bisphosphonates and RANKL Antibody Denosumab’).Inside the INSEMA analyze – a prospectively randomized research comparing SLNE vs. no SLNE in clients with early i